HTR2B | 5-hydroxytryptamine (serotonin) receptor 2B, G protein-coupled | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
HTR3A | 5-hydroxytryptamine (serotonin) receptor 3A, ionotropic | FDA approved drug targets Predicted membrane proteins Predicted secreted proteins Transporters
| | | | | Group enriched |
KCNA2 | Potassium voltage-gated channel, shaker-related subfamily, member 2 | FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
KCNA3 | Potassium voltage-gated channel, shaker-related subfamily, member 3 | FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
KCNA5 | Potassium voltage-gated channel, shaker-related subfamily, member 5 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
KCNB1 | Potassium voltage-gated channel, Shab-related subfamily, member 1 | FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNC3 | Potassium voltage-gated channel, Shaw-related subfamily, member 3 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
KCND2 | Potassium voltage-gated channel, Shal-related subfamily, member 2 | FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCND3 | Potassium voltage-gated channel, Shal-related subfamily, member 3 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
KCNH2 | Potassium voltage-gated channel, subfamily H (eag-related), member 2 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNJ1 | Potassium inwardly-rectifying channel, subfamily J, member 1 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enriched |
KCNJ8 | Potassium inwardly-rectifying channel, subfamily J, member 8 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
KCNK3 | Potassium channel, subfamily K, member 3 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNN4 | Potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 | FDA approved drug targets Predicted membrane proteins Predicted secreted proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNQ1 | Potassium voltage-gated channel, KQT-like subfamily, member 1 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNQ2 | Potassium voltage-gated channel, KQT-like subfamily, member 2 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
KCNQ3 | Potassium voltage-gated channel, KQT-like subfamily, member 3 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enriched |
MC2R | Melanocortin 2 receptor (adrenocorticotropic hormone) | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Tissue enriched |
MS4A1 | Membrane-spanning 4-domains, subfamily A, member 1 | CD markers Disease related genes FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Group enriched |
MTNR1A | Melatonin receptor 1A | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
PTGER1 | Prostaglandin E receptor 1 (subtype EP1), 42kDa | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
RYR1 | Ryanodine receptor 1 (skeletal) | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SCN11A | Sodium channel, voltage-gated, type XI, alpha subunit | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
SCN1A | Sodium channel, voltage-gated, type I, alpha subunit | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
SCN2A | Sodium channel, voltage-gated, type II, alpha subunit | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enriched |
SCN2B | Sodium channel, voltage-gated, type II, beta subunit | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Group enriched |
SCN4A | Sodium channel, voltage-gated, type IV, alpha subunit | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
SCN4B | Sodium channel, voltage-gated, type IV, beta subunit | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Mixed |
SCN5A | Sodium channel, voltage-gated, type V, alpha subunit | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enriched |
SCN9A | Sodium channel, voltage-gated, type IX, alpha subunit | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
SCNN1A | Sodium channel, non-voltage-gated 1 alpha subunit | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Mixed |
SCNN1B | Sodium channel, non-voltage-gated 1, beta subunit | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Mixed |
SCNN1G | Sodium channel, non-voltage-gated 1, gamma subunit | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
SCTR | Secretin receptor | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
SLC12A1 | Solute carrier family 12 (sodium/potassium/chloride transporter), member 1 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC12A2 | Solute carrier family 12 (sodium/potassium/chloride transporter), member 2 | FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Expressed in all |
SLC12A3 | Solute carrier family 12 (sodium/chloride transporter), member 3 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC12A4 | Solute carrier family 12 (potassium/chloride transporter), member 4 | FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Expressed in all |
SLC12A5 | Solute carrier family 12 (potassium/chloride transporter), member 5 | FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC18A1 | Solute carrier family 18 (vesicular monoamine transporter), member 1 | FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC18A2 | Solute carrier family 18 (vesicular monoamine transporter), member 2 | FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Expressed in all |
SLC22A11 | Solute carrier family 22 (organic anion/urate transporter), member 11 | FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Group enriched |
SLC22A6 | Solute carrier family 22 (organic anion transporter), member 6 | FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC22A8 | Solute carrier family 22 (organic anion transporter), member 8 | FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC25A4 | Solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 4 | Disease related genes FDA approved drug targets Mitochondrial proteins Predicted membrane proteins Transporters
| | | | | Group enriched |
SLC25A5 | Solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 5 | FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted membrane proteins Transporters
| | | | | Expressed in all |
SLC25A6 | Solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 6 | FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted membrane proteins Transporters
| | | | | Expressed in all |
SLC52A2 | Solute carrier family 52 (riboflavin transporter), member 2 | Disease related genes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins Transporters
| | | | | Expressed in all |
SLC5A2 | Solute carrier family 5 (sodium/glucose cotransporter), member 2 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC6A1 | Solute carrier family 6 (neurotransmitter transporter), member 1 | FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Group enriched |